Efficacy of Pentavalent Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Infants in Developing Countries in Sub-Saharan Africa: A Randomised, Double-Blind, Placebo-Controlled Trial

This article, published in The Lancet, shares results of an efficacy study of the pentavalent, live oral rotavirus vaccine in Ghana, Kenya, and Mali. Results showed 39.3 percent efficacy against  severe rotavirus gastroenteritis. The authors concluded that the vaccine is effective against severe rotavirus gastroenteritis among African infants during the first two years of life in countries with high mortality in children younger than five years, and the results support the expanded World Health Organization recommendation to promote its global use. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author(s): Armah GE, Sow SO, Breiman RF, et al.

Published: 2010

  • Visit web page (English)

    (Located at www.thelancet.com)

    Citation: Armah GE, Sow SO, Breiman RF, et al. Efficacy of Pentavalent Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Infants in Developing Countries in Sub-Saharan Africa: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet. 2010:376(9741);606-614.